# Ponatinib Hcl (Iclusig)

Source: https://ourhealthnetwork.com/drugs/ponatinib-hcl
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Ponatinib Hcl?

Ponatinib Hcl (brand name: Iclusig) is a kinase inhibitor. It is prescribed to treat leukemia, myeloid.

## Brand names

Iclusig

## Indications

Ponatinib Hcl is prescribed for the treatment of leukemia and myeloid.

## Conditions treated

- [Leukemia](https://ourhealthnetwork.com/conditions/leukemia)
- [Myeloid](https://ourhealthnetwork.com/conditions/myeloid)

## Mechanism of action

Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.

## Drug classification

- Established Pharmacologic Class: kinase inhibitors
- Route of administration: ORAL

## Common side effects

abdominal pain, arthralgia, constipation, dry skin, fatigue, fluid retention and edema, headache, hepatotoxicity

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)